Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme

Biochemical Pharmacology

Volumn 71, Issue 1-2, 2005, Pages 74-88

  Mailliet, François ^a   Ferry, Gilles ^a   Vella, Fanny ^a   Berger, Sylvie ^a   Cogé, Francis ^a   Chomarat, Pascale ^a   Mallet, Catherine ^a   Guénin, Sophie Pénélope ^a   Guillaumet, Gérald ^b   Viaud Massuard, Marie Claude ^c   Yous, Saïd ^d   Delagrange, Philippe ^e   Boutin, Jean A ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b UNIVERSITÉ D'ORLÉANS   (France)

^c UNIVERSITÉ DE TOURS   (France)

^d UNIV LILLE   (France)

^e INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

Binding; Inhibitors; Melatonin; Molecular pharmacology; MT3; Quinone reductase 2

Indexed keywords

[2 (2 METHOXY 6H DIPYRIDO[2,3 A:3,2 E]PYRROLIZIN 11 YL)ETHYL] 2 FURAMIDE; DIHYDRONICOTINAMIDE RIBOSIDE:QUINONE OXIDOREDUCTASE 2; MELATONIN; OXIDOREDUCTASE; PYRROLIZINE DERIVATIVE; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG; NRH - QUINONE OXIDOREDUCTASE2; NRH QUINONE OXIDOREDUCTASE2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CATALYSIS; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BINDING COMPETITION; CHO CELL; HAMSTER; METABOLISM;

ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; MELATONIN; QUINONE REDUCTASES;

EID: 28244496559     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.09.030     Document Type: Article

References (50)

1. Arendt J Melatonin Clin Endocrinol 29 1988 205 229
2. P. Delagrange, J. Atkinson, J.A. Boutin, L. Casteilla, D. Lesieur, and R. Misslin Therapeutic perspectives for melatonin agonists and antagonists J Neuroendocrinol 15 2003 442 448
3. M.L. Dubocovich, D.P. Cardinali, P. Delagrange, D.N. Krause, D. Strosberg, and D. Sugden Melatonin receptors. The IUPHAR compendium of receptor characterization and classification 2000 IUPHAR Media London p. 270-7
4. 125I] iodomelatonin binding sites in hamster brain membranes: pharmacological characteristics and regional distribution Endocrinology 122 1988 1825 1833
5. F. Mailliet, V. Audinot, B. Malpaux, P. Delagrange, M. Migaud, and P. Barrett Molecular pharmacology of ovine melatonin receptor: comparison with recombinant human MT1 and MT2 Biochem Pharmacol 67 2004 667 677
6. 125I] iodomelatonin binding sites in hamster brain membranes: pharmacological characteristics and regional distribution Endocrinology 122 1988 1825 1833
7. 125I]iodomelatonin binding sites in Djungarian hamster brain Endocrinology 125 1989 1011 1018
8. D.S. Pickering, and L.P. Niles Pharmacological characterization of melatonin binding sites in Syrian hamster hypothalamus Eur J Pharmacol 175 1990 71 77
9. 125I]iodomelatonin binding sites in Syrian hamster peripheral organs J Pharmacol Exp Ther 290 1999 334 340
10. M.L. Dubocovich Pharmacology and function of melatonin receptors FASEB J 2 1988 2765 2773
11. M.L. Dubocovich Melatonin receptors: are there multiple subtypes? Trends Pharmacol Sci 16 1995 50 56
12. 125I]iodo-5- methoxycarbonylamino-N-acetyltryptamine: a selective radioligand for the characterization of melatonin ML2 binding sites Eur J Pharmacol 301 1996 159 168
13. 3 as the quinone reductase 2 J Biol Chem 275 2000 31311 31317
14. 3/QR2 Biochem Pharmacol 61 2001 1369 1379
15. 3 receptors in the regulation of intraocular pressure in rabbits Eur J Pharmacol 416 2001 251 254
16. 3 receptor Br J Pharmacol 138 2003 831 836
17. J.B. Serle, R.F. Wang, W.M. Peterson, R. Plourde, and B.R. Yerxa Effect of 5-MCA-NAT, a putative melatonin MT3 receptor agonist, on intraocular pressure in glaucomatous monkey eyes J Glaucoma 13 2004 385 388
18. 3 FEBS Lett 578 2004 116 120
19. A.T. Dinkova-Kostova, and P. Talalay Persuasive evidence that quinone reductase type 1 (DT diaphorase) protects cells against the toxicity of electrophiles and reactive forms of oxygen Free Radic Biol Med 29 2000 231 240
20. D.J. Long, K. Iskander, A. Gaikwad, M. Arin, D.R. Roop, and R. Knox Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity J Biol Chem 277 2002 46131 46139
21. D. Pozo, R.J. Reiter, J.R. Calvo, and J.M. Guerrero Physiological concentrations of melatonin inhibit nitric oxide synthase in rat cerebellum Life Sci 55 1994 L455 L460
22. R.J. Reiter, D. Melchiorri, E. Sewerynek, B. Poeggeler, L. Barlow-Walden, and J. Chuang A review of the evidence supporting melatonin's role as an antioxidant J Pineal Res 18 1995 1 11
23. L.R. Barlow-Walden, R.J. Reiter, M. Abe, M. Pablos, A. Menendez-Pelaez, and L.D. Chen Melatonin stimulates brain glutathione peroxidase activity Neurochem Int 26 1995 497 502
24. J. Cabeza, V. Motilva, M.J. Martin, and C.A. de la Lastra Mechanisms involved in gastric protection of melatonin against oxidant stress by ischemia-reperfusion in rats Life Sci 68 2001 1405 1415
25. S. Liao, J.T. Dulanet, and H.G. Williams-Ashman Purification and properties of a flavoprotein catalyzing the oxidation of reduced ribosyl nicotinamide J Biol Chem 237 1962 2981 2987
26. C.E. Foster, M.A. Bianchet, P. Talalay, M. Faig, and L.M. Amzel Structures of mammalian cytosolic quinone reductases Free Radic Biol Med 29 2000 241 245
27. K. Wu, R. Knox, X.Z. Sun, P. Joseph, A.K. Jaiswal, and D. Zhang Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase Arch Biochem Biophys 347 1997 221 228
28. Q. Zhao, X.L. Yang, W.D. Holtzclaw, and P. Talalay Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to NAD(P)H:quinone reductase (DT-diaphorase) Proc Natl Acad Sci USA 94 1997 1669 1674
29. M.A. Bianchet, C. Foster, M. Faig, P. Talalay, and L.M. Amzel Structure and mechanism of cytosolic quinone reductases Biochem Soc Trans 27 1999 610 615
30. C.E. Foster, M.A. Bianchet, P. Talalay, Q. Zhao, and L.M. Amzel Crystal structure of human quinone reductase type 2, a metalloflavoprotein Biochemistry 38 1999 9881 9886
31. J.J. Kwiek, Haystead TAJ, and J. Rudolph Kinetic mechanism of quinone reductase 2 and its inhibition by the antimalarial quinolines Biochemistry 43 2004 4538 4547
32. L. Buryanovskyy, Y. Fu, M. Boyd, Y. Ma, T.C. Hsieh, and J.M. Wu Crystal structure of quinone reductase 2 in complex with resveratrol Biochemistry 43 2004 11417 11426
33. Vella F, Ferry G, Delagrange P, Boutin JA. NRH:quinone reductase 2: an, enzyme of surprises and mysteries. Biochem Pharmacol, in press.
34. V. Leclerc, S. Yous, P. Delagrange, J.A. Boutin, P. Renard, and D. Lesieur Synthesis of nitroindole derivatives with high affinity and selectivity for melatoninergic binding sites MT(3) J Med Chem 45 2002 1853 1859
35. Lesieur D, Klupsch F, Guillaumet G, Viaud MC, Langlois M, Bennejean C, et al. Preparation of heteroarylcarboxylates and analogs as melatonin receptor ligands. International Patent Application WO 9958496 (November 18, 1999).
36. V. Wallez, S. Durieux-Poissonnier, P. Chavatte, J.A. Boutin, V. Audinot, and J.P. Nicolas Synthesis and structure-activity relationships of novel benzofuran derivatives as MT(2) melatonin receptor selective ligands J Med Chem 45 2002 2788 2800
37. I. Charton, A. Mamai, C. Bennejean, P. Renard, P. Delagrange, and P.J. Morgan Synthesis and biological activity of new melatonin receptor ligands Pharm Pharmacol Commun 6 2000 49 60
38. Viaud MC, Guillaumet G, Mazeas D, Vandepoel H, Renard P, Pfeiffer B, et al. Preparation of N-(pyrrolopyridylalkyl)alkanamides and analogs as melatonin receptor ligands. European Patent EP 737685 (October 16, 1996).
39. Guillaumet G, Viaud MC, Van De Poel H, Delagrange P, Bennejean C, Renard P. Preparation of polycyclic azaindole derivatives and their affinity for melatonin receptors European Patent EP 1092717 (April 18, 2001).
40. M. Bradford A rapid and sensitive method for the quantification of micrograms quantities of protein utilizing the principle of protein-dye binding Anal Biochem 72 1976 248 254
41. G. Scatchard The attraction of protein for small molecules and ions Ann NY Acad Sci 51 1949 660 672
42. 50) of an enzymatic reaction Biochem Pharmacol 22 1973 3099 3108
43. J.A. Boutin, F. Chatelain-Egger, F. Vella, P. Delagrange, and G. Ferry Quinone reductase 2 substrates, cosubstrates and inhibitors Chemico-Biol Int 151 2005 213 228
44. K. Teshima, and T. Kondo Analytical method for ubiquinone-9 and ubiquinone-10 in rat tissues by liquid chromatography/turbo ion spray tandem mass spectrometry with 1-alkylamine as an additive to the mobile phase Anal Biochem 338 2005 12 19
45. Y. Suhara, M. Kamao, N. Tsugawa, and T. Okano Method for the determination of vitamin K homologues in human plasma using high-performance liquid chromatography-tandem mass spectrometry Anal Chem 77 2005 757 763
46. J.A. Boutin, V. Audinot, G. Ferry, and P. Delagrange Molecular tools to study melatonin pathways and actions Trends Pharmacol Sci 26 2005 412 419
47. D.J. Long, and A.K. Jaiswal Mouse NRH:quinone oxidoreductase (NQO2): cloning of cDNA and gene- and tissue-specific expression Gene 252 2000 107 117
48. M. Degli-Esposito, G. Ferry, P. Masdehors, J.A. Boutin, J. Hickman, and C. Dive Post-translational modification of Bid has differential effects on its susceptibility to cleavage by caspase 8 or caspase 3 J Biol Chem 278 2003 15749 15757
49. J.A. Boutin Myristoylation Cell Signal 9 1997 15 35
50. S. Colombo, R. Longhi, S. Alcaro, F. Ortuso, T. Sprocati, and A. Flora N-myristoylation determines dual targeting of mammalian NADH-cytochrome b(5) reductase to ER and mitochondrial membranes by a mechanism of kinetic partitioning J Cell Biol 168 2005 735 745